GlassScriptPhysician profile
Amanda R Stephens
NPI 1437449584
$735.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.34 · 2020: $311 · 2021: $117 · 2022: $213.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $308.93 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $214.58 | 2019-2022 | |
| Genzyme Corporation | $80.95 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $35.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2022 | |
| Genentech USA, INC. | $14.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.70 | 2020 | |
| Olympus America INC. | $13.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.11 | 2022 | |
| Kaleo, INC. | $12.95 | 2022 | |
| Csl Behring | $12.49 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.